Atopic Dermatitis Clinical Trial
Official title:
The Epidemiology of Atopic Dermatitis, Associated Comorbidities, and Treatment Patterns in the United Kingdom (UK)
Atopic dermatitis, commonly called eczema, is one of the most frequently occurring skin
conditions. It is estimated to affect around one fifth of children in developed countries and
is also becoming increasingly common in less developed countries. Exact estimates of how
common eczema is, vary considerably and there has not been an in-depth analysis of the number
of people with eczema in the UK. It is also unclear which groups of people are most affected
and which treatment options are being used.
Most people with eczema are managed by their general practitioner (GP) with only a few people
requiring specialist care. GP records therefore provide an excellent opportunity to explore
how common eczema is and which treatments are being used currently. This study aims to
provide accurate estimates of the number of people with current eczema (prevalence), number
developing new onset eczema (incidence), and the pattern of common comorbidities in people
with eczema. It also aims describe current treatment patterns by age groups and other
factors. It also will look back over the last decade to identify how the number of people
with eczema and treatments changing over time. The study will also explore patterns in the
people most commonly affected and in the treatments used.
Objective
This study aims to calculate current and accurate prevalence and incidence estimates for
atopic dermatitis (AD) by age group and sociodemographic factors. It also aims to describe
the burden of comorbidity in AD with a focus on atopic and mental health conditions. The
study also aims to describe the health care resource utilisation of this cohort in terms of
prescription use, primary care appointments, and specialist referrals.
Method This study will define AD cases using a previously validated algorithm for case
identification use clinical codes form primary care in the UK (Read codes). The study will
analyse the population prevalence and incidence of AD using this definition over a 10-year
period (2008-2018). Within this population the prevalence of autoimmune conditions
(rheumatoid arthritis, inflammatory bowel disease, coeliac disease, type 1 diabetes, and
multiple sclerosis) will be reported and compared with a cohort of individuals without a
diagnosis of AD, matched by age and sex at GP practice level. In the same cohort, the annual
use of topical and oral medications used for the treatment of AD, primary care appointments,
and specialist referrals, overall and stratified by sociodemographic factors will also be
reported.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
| Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
| Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
| Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
| Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
| Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
| Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
| Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
| Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
| Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
| Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
| Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
| Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
| Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
| Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
| Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |